GIPR: the Crucial Regulator of Glucose and Lipid Metabolism in Diabetes and Obesity!

GIPR: the Crucial Regulator of Glucose and Lipid Metabolism in Diabetes and Obesity!

GIPR belongs to G protein-coupled receptors (GPCRs) consisting of seven transmembrane domains. GPCRs have been widely reported to regulate various diseases (eg. CCR4, CCR8, GPRC5D, CXCR4, GCGR, SSTR2). GIPR serves as the receptor for GIP. GIP and GLP-1 act on the corresponding receptors of pancreatic β cells, GIPR and GLP-1R, respectively, to regulate β cells functions. As for GIPR, current studies have demonstrated the significant role of GIPR in glucose and lipid metabolism, showing great potential in the fight against diabetes and obesity! (Click to Read More about GIPR)

A GIPR based drug (Tirzepatide) has been approved for treating type 2 diabetes, obesity, and cardiovascular disease, etc. Now, over 40 GIPR-targeted drugs is in clinical studies worldwide, developed by companies like Eli Lilly, Amgen, Carmot Therapeutics etc. These drugs come in different forms, including antibodies, peptide-coupled drugs, and fusion proteins. Most of them work by either activating or inhibiting GIPR. Some of them have additional effects, such as GLP-1R agonism, GCGR agonism etc. Thus, more GIPR-based drugs are expected to emerge in the future! (Click for GIPR Clinical Trials for Drug Development)

To fully support researchers and pharmaceutical companies in their research on GIPR in diabetes, obesity, and cancers, CUSABIO presents GIPR active protein to support your research on the mechanism of GIPR or its potential clinical value (click for the full list of GIPR products: GIPR Proteins; GIPR antibodies).

Recombinant Mouse Gastric inhibitory polypeptide receptor(Gipr),partial (Active) (Code: CSB-MP009438MO1) High Specificity Validated by SDS-PAGE Excellent Bioactivity Validated by Functional ELISA High specificity was validated by SDS-PAGE. SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Immobilized Mouse Gipr at 2μg/mL can bind Anti-Mouse Gipr recombinant antibody (CSB-RA009438MA1MO), the EC50 is 8.622-11.36 ng/mL.

Recombinant Rat Gastric inhibitory polypeptide receptor(Gipr),partial (Active) (Code: CSB-MP009438RA1) High Specificity Validated by SDS-PAGE Excellent Bioactivity Validated by Functional ELISA High specificity was validated by SDS-PAGE. SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Immobilized Rat Gipr at 2μg/mL can bind Anti-Mouse Gipr recombinant antibody (CSB-RA009438MA1MO), the EC50 is 6.946-8.740 ng/mL.

GIPR Clinical Trials for Drug Development Drugs Target Mechanism of action Indications Status Drug Type Institutes Tirzepatide GIPR+GLP-1R GIPR agonist; GLP-1R agonist Type 2 diabetes; overweight; obstructive sleep apnea syndrome; cardiovascular disease; Obesity Approval for listing Synthetic peptides Ei Lilly & Co; Ei Lily Japan KK; Eli Lilly Suzhou Pharmaceutical Co. Retatrutide GCGR +GIPR GCGR agonist; GLP-1R agonist Cardiovascular disease; obesity; overweight; type 2 diabetes Clinical Phase 3 Synthetic peptides Ei Lilly & Co; Lilly Suzhou Pharmaceutical Co. Maridebart Cafraglutide GIPR+GLP-1R GIPR antagonist; GLP-1R agonist Type 2 diabetes; obesity; overweight Clinical Phase 2 Peptide-coupled drugs (PDC) Amgen, Inc. LY-3537031 GIPR+GlP-1R GIPR agonist, GLP-1R agonist / Clinical Phase 1 Synthetic peptides Ei Lilly & Co CT-388 GIPR+GlP-1R GIPR agonist, GLP-1R modulator Diabetes mellitus; type 2 diabetes; obesity; non-alcoholic steatohepatitis Clinical Phase 1 Synthetic peptides Carmot Therapeutics, Inc. DR10627 GIPR+GlP-1R GIPR agonist, GLP-1R modulator Diabetes mellitus; non-alcoholic steatohepatitis Clinical Phase 1 Synthetic peptides Zhejiang Doer Biologics Co. GMA-106 GIPR+GlP-1R GIPR antagonist, GLP-1R antagonist Pulmonary sedation; type 2 diabetes; nonalcoholic steatohepatitis; obesity; overweight Clinical Phase 1 Bispecific antibodies Gmax Biopharm (Hangzhou) Co. Maridebart GIPR GIPR antagonists Tumors Clinical phase no Monoclonal antibodies / Efocipegtrutide GIPR+GlP-1R GIPR agonist, GLP-1R agonist / Clinical phase no Fusion proteins / DR10628 GIPR+GlP-1R GIPR agonist, GLP-1R agonist Diabetes mellitus; non-alcoholic steatohepatitis Preclinical Fusion proteins Zhejiang Doer Biologics Co. HDM-1005 GIPR+GlP-1R GIPR agonist, GLP-1R agonist Diabetes; obesity Preclinical Bispecific antibodies Huadong Medicine Co. 111In-3BP tracer GIPR GIPR antagonists Neuroendocrine tumors Preclinical Synthetic peptides 3B Pharmaceuticals GmbH DR10625 FGF21 + GIPR + GLP-1R FGF21 modulator, GIPR agonist, GLP-1R agonist Obesity; type 2 diabetes mellitus; nonalcoholic steatohepatitis Preclinical Fusion proteins Zhejiang Doer Biologics Co. XW-017 GIPR GIPR agonist Obesity; type 2 diabetes mellitus; nonalcoholic steatohepatitis Preclinical Synthetic peptides Hangzhou Sciwind Biosciences Co. LBT-6030 GIPR+GlP-1R GIPR agonist, GLP-1R agonist Diabetes Preclinical Biologics Longevity Biotech, Inc. 3B-402 GIPR GIPR modulators Neuroendocrine tumors Drug Discovery Synthetic peptides 3B Pharmaceuticals GmbH 3B-401 GIPR GIPR modulators Neuroendocrine tumors Drug Discovery Synthetic peptides 3B Pharmaceuticals GmbH ZP-3022 (Zealand Pharma A/S) GCGR + GIPR + GLP-1R + NPY GCGR modulators, GIPR agonists, GLP-1R agonists / Preclinical Biologics / ZP-1-98 (Zealand Pharma A/S) GIPR GIPR agonist / Preclinical Biologics / CYT-014-GIPQb GIPR GIPR modulators / Drug Discovery Biologics /

CUSABIO appreciates the critical role that you and our products play in research since many scientists are diligently pursuing their research to further scientific innovation and discovery. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.